These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
482 related articles for article (PubMed ID: 25733192)
1. 5-Aminosalicylic acid, a specific drug for ulcerative colitis. Hauso Ø; Martinsen TC; Waldum H Scand J Gastroenterol; 2015 Aug; 50(8):933-41. PubMed ID: 25733192 [TBL] [Abstract][Full Text] [Related]
2. Inducing and maintaining remission in ulcerative colitis: role of high-dose, extended-release mesalamine. Kao J; Kwok K; Das KM J Clin Gastroenterol; 2010 Sep; 44(8):531-5. PubMed ID: 20495466 [TBL] [Abstract][Full Text] [Related]
3. The metabolism of mesalamine and its possible use in colonic diverticulitis as an anti-inflammatory agent. Cohen HD; Das KM J Clin Gastroenterol; 2006 Aug; 40 Suppl 3():S150-4. PubMed ID: 16885699 [TBL] [Abstract][Full Text] [Related]
4. Encapsulated mesalamine granules (Apriso) for ulcerative colitis. Med Lett Drugs Ther; 2009 May; 51(1312):38-9. PubMed ID: 19448588 [TBL] [Abstract][Full Text] [Related]
5. [5-aminosalicylic acid in the treatment of ulcerative colitis and Crohn's disease]. Moum B Tidsskr Nor Laegeforen; 2003 Sep; 123(18):2565-7. PubMed ID: 14714043 [TBL] [Abstract][Full Text] [Related]
6. Measurement of colonic mucosal concentrations of 5-aminosalicylic acid is useful for estimating its therapeutic efficacy in distal ulcerative colitis: comparison of orally administered mesalamine and sulfasalazine. Naganuma M; Iwao Y; Ogata H; Inoue N; Funakoshi S; Yamamoto S; Nakamura Y; Ishii H; Hibi T Inflamm Bowel Dis; 2001 Aug; 7(3):221-5. PubMed ID: 11515848 [TBL] [Abstract][Full Text] [Related]
7. Putting rectal 5-aminosalicylic acid in its place: the role in distal ulcerative colitis. Marshall JK; Irvine EJ Am J Gastroenterol; 2000 Jul; 95(7):1628-36. PubMed ID: 10925961 [TBL] [Abstract][Full Text] [Related]
8. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Sutherland L; Macdonald JK Cochrane Database Syst Rev; 2006 Apr; (2):CD000543. PubMed ID: 16625536 [TBL] [Abstract][Full Text] [Related]
9. Evaluation of 5-aminosalicyltaurine as a colon-specific prodrug of 5-aminosalicylic acid for treatment of experimental colitis. Jung Y; Kim HH; Kim H; Kong H; Choi B; Yang Y; Kim Y Eur J Pharm Sci; 2006 May; 28(1-2):26-33. PubMed ID: 16455235 [TBL] [Abstract][Full Text] [Related]
10. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Sutherland L; MacDonald JK Cochrane Database Syst Rev; 2003; (3):CD000543. PubMed ID: 12917894 [TBL] [Abstract][Full Text] [Related]
11. The role of aminosalicylates in the treatment of ulcerative colitis. Van Assche G; Baert F; De Reuck M; De Vos M; De Wit O; Hoang P; Louis E; Mana F; Pelckmans P; Rutgeerts P; Van Gossum A; D'Haens G Acta Gastroenterol Belg; 2002; 65(4):196-9. PubMed ID: 12619425 [TBL] [Abstract][Full Text] [Related]
12. 5-aminosalicylic acid given in the remission stage of colitis suppresses colitis-associated cancer in a mouse colitis model. Ikeda I; Tomimoto A; Wada K; Fujisawa T; Fujita K; Yonemitsu K; Nozaki Y; Endo H; Takahashi H; Yoneda M; Inamori M; Kubota K; Saito S; Nagashima Y; Nakagama H; Nakajima A Clin Cancer Res; 2007 Nov; 13(21):6527-31. PubMed ID: 17975166 [TBL] [Abstract][Full Text] [Related]
13. Clinical trial: ulcerative colitis maintenance treatment with 5-ASA: a 1-year, randomized multicentre study comparing MMX with Asacol. Prantera C; Kohn A; Campieri M; Caprilli R; Cottone M; Pallone F; Savarino V; Sturniolo GC; Vecchi M; Ardia A; Bellinvia S Aliment Pharmacol Ther; 2009 Nov; 30(9):908-18. PubMed ID: 19678813 [TBL] [Abstract][Full Text] [Related]
14. Treatment of ulcerative colitis with oral mesalamine: advances in drug formulation, efficacy expectations and dose response, compliance, and chemoprevention. Sandborn WJ Rev Gastroenterol Disord; 2006; 6(2):97-105. PubMed ID: 16699478 [TBL] [Abstract][Full Text] [Related]
15. Addition of Berberine to 5-Aminosalicylic Acid for Treatment of Dextran Sulfate Sodium-Induced Chronic Colitis in C57BL/6 Mice. Li YH; Zhang M; Xiao HT; Fu HB; Ho A; Lin CY; Huang Y; Lin G; Bian ZX PLoS One; 2015; 10(12):e0144101. PubMed ID: 26642326 [TBL] [Abstract][Full Text] [Related]
16. Mesalamine with MMX technology for the treatment of ulcerative colitis. Schreiber S; Kamm MA; Lichtenstein GR Expert Rev Gastroenterol Hepatol; 2008 Jun; 2(3):299-314. PubMed ID: 19072380 [TBL] [Abstract][Full Text] [Related]
17. The systemic load and efficient delivery of active 5-aminosalicylic acid in patients with ulcerative colitis on treatment with olsalazine or mesalazine. Støa-Birketvedt G; Florholmen J Aliment Pharmacol Ther; 1999 Mar; 13(3):357-61. PubMed ID: 10102969 [TBL] [Abstract][Full Text] [Related]
18. Adverse effects of sulfasalazine and treatment of ulcerative colitis with mesalazine. Nakajima H; Munakata A; Yoshida Y J Gastroenterol; 1995 Nov; 30 Suppl 8():115-7. PubMed ID: 8563870 [TBL] [Abstract][Full Text] [Related]
19. Mesalamine restores angiogenic balance in experimental ulcerative colitis by reducing expression of endostatin and angiostatin: novel molecular mechanism for therapeutic action of mesalamine. Deng X; Tolstanova G; Khomenko T; Chen L; Tarnawski A; Szabo S; Sandor Z J Pharmacol Exp Ther; 2009 Dec; 331(3):1071-8. PubMed ID: 19762547 [TBL] [Abstract][Full Text] [Related]
20. Birth outcome in women with ulcerative colitis and Crohn's disease, and pharmacoepidemiological aspects of anti-inflammatory drug therapy. Nørgård BM Dan Med Bull; 2011 Dec; 58(12):B4360. PubMed ID: 22142578 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]